Why Insmed Incorporated (INSM) stock moved
Insmed Incorporated (INSM) shares fell 1.2% to $107.02 as of July 21, 2026, a modest decline from the prior close of $108.32. BestStocks flagged the session as a major change for INSM. Below, we break down what changed for INSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
INSM fell 1.2% to $107.02
INSM fell 1.2% in its latest session, moving from $108.32 to $107.02.
What it means for Insmed Incorporated investors
For Insmed Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Insmed Incorporated (INSM) moved +1.48% from $116.53 to $118.26 on 2026-07-09, reaching a new 30-day high; INSM moved +3.27% from $112.84 to $116.53 on 2026-07-08. Weighing against that: Negative session, down 1.2%; Insmed Incorporated (INSM) moved -5.60% from $115.61 to $109.14 on 2026-07-13. Wall Street's consensus price target sits at $200.50, implying +87.3% upside from $107.02. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 16 days out, the next report is the most likely near-term test of the move.
INSM price reaction
INSM last traded at $107.02, down $1.30 (-1.20%) from the previous close of $108.32. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $98.61 and $118.26, and it currently sits about 43% of the way up that band.
Bullish and bearish analyst opinions on Insmed Incorporated (INSM)
The consensus analyst price target on Insmed Incorporated (INSM) is $200.50, 87.3% above the recent $107.02. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on INSM line up.
The bullish case
- Wall Street's consensus price target of $200.50 implies +87.3% upside from $107.02.
- The Street's most bullish target is $231.00 (+115.8%).
- Insmed Incorporated (INSM) moved +1.48% from $116.53 to $118.26 on 2026-07-09, reaching a new 30-day high.
- INSM moved +3.27% from $112.84 to $116.53 on 2026-07-08.
- INSM moved +1.17% from $111.54 to $112.84 on 2026-07-07.
The bearish case
- Negative session, down 1.2%.
- Insmed Incorporated (INSM) moved -5.60% from $115.61 to $109.14 on 2026-07-13.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for INSM
Frequently asked questions about INSM
Why did Insmed Incorporated (INSM) stock move?
INSM fell 1.2% to $107.02. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did INSM stock fall?
INSM lost 1.20% ($1.30) versus the prior close of $108.32, last trading at $107.02 on 0.5× average volume.
When is Insmed Incorporated's next earnings date?
INSM's next earnings report is estimated for 2026-08-06 — about 16 days away.
What is the analyst price target for INSM?
The consensus analyst price target for INSM is $200.50, about 87.3% above the current $107.02. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks INSM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared INSM-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for INSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.